Imexpharm (STC:IMP) Cyclically Adjusted Revenue per Share: ₫11,776.55 (As of Mar. 2026)


STC:IMP Imexpharm Corp STC:IMP
97 GF Score
Price ₫42,950.00
GF Value ₫52,149.61
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Cyclically Adjusted Revenue per Share?

Imexpharm STC:IMP +0.59% 97 Cyclically Adjusted Revenue per Share is ₫11,776.55 as of Mar. 2026. GuruFocus rates STC:IMP with a GF Score™ of 97/100 and a GF Value™ of ₫52,149.61 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Imexpharm's adjusted revenue per share for the three months ended in Mar. 2026 was ₫3,546.587. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₫11,776.55 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Imexpharm's average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Imexpharm was 4.70% per year. The lowest was 4.50% per year. And the median was 4.60% per year.

As of today (2026-07-05), Imexpharm's current stock price is ₫42950.00. Imexpharm's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₫11,776.55. Imexpharm's Cyclically Adjusted PS Ratio of today is 3.65.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Imexpharm was 4.85. The lowest was 2.00. And the median was 3.41.


Imexpharm  (STC:IMP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Imexpharm's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=42950.00/11776.55
=3.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Imexpharm was 4.85. The lowest was 2.00. And the median was 3.41.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Imexpharm Cyclically Adjusted Revenue per Share Related Terms


Imexpharm Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Imexpharm's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Cyclically Adjusted Revenue per Share Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,455.19 9,958.50 10,415.62 10,788.70 11,443.75

Imexpharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,064.11 11,279.03 11,488.60 11,443.75 11,776.55

STC:IMP vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imexpharm Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Imexpharm's Cyclically Adjusted PS Ratio falls into.


STC:IMP
97GF Score
Imexpharm Corp STC:IMP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Imexpharm's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3546.587/330.2130*330.2130
=3,546.587

Current CPI (Mar. 2026) = 330.2130.

Imexpharm Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2,048.091 241.018 2,806.041
201609 1,865.477 241.428 2,551.505
201612 2,344.301 241.432 3,206.363
201703 2,030.552 243.801 2,750.254
201706 1,612.329 244.955 2,173.509
201709 1,465.050 246.819 1,960.054
201712 2,691.059 246.524 3,604.609
201803 1,932.959 249.554 2,557.716
201806 1,520.126 251.989 1,992.013
201809 1,968.838 252.439 2,575.418
201812 2,487.264 251.233 3,269.184
201903 1,813.382 254.202 2,355.616
201906 1,669.003 256.143 2,151.636
201909 2,527.505 256.759 3,250.577
201912 3,426.961 256.974 4,403.664
202003 2,047.692 258.115 2,619.664
202006 1,711.778 257.797 2,192.622
202009 1,556.627 260.280 1,974.867
202012 3,162.207 260.474 4,008.853
202103 1,924.778 264.877 2,399.554
202106 1,813.625 271.696 2,204.238
202109 1,462.653 274.310 1,760.734
202112 2,574.600 278.802 3,049.355
202203 2,040.407 287.504 2,343.511
202206 1,955.390 296.311 2,179.113
202209 2,305.288 296.808 2,564.742
202212 3,617.664 296.797 4,024.972
202303 3,111.954 301.836 3,404.523
202306 2,646.383 305.109 2,864.124
202309 2,813.383 307.789 3,018.352
202312 3,664.920 306.746 3,945.298
202403 3,188.783 312.332 3,371.341
202406 2,887.245 314.175 3,034.633
202409 3,039.331 315.301 3,183.075
202412 3,638.474 315.605 3,806.883
202503 3,857.297 319.799 3,982.907
202506 3,531.496 322.561 3,615.272
202509 3,200.001 324.800 3,253.331
202512 3,737.737 324.054 3,808.777
202603 3,546.587 330.213 3,546.587

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₫11,776.55 mean?
Imexpharm (STC:IMP) has a Cyclically Adjusted Revenue per Share of ₫11,776.55 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Imexpharm and its competitors.
Is Imexpharm's Cyclically Adjusted Revenue per Share too high?
Imexpharm's current Cyclically Adjusted Revenue per Share is ₫11,776.55. Overall, Imexpharm has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Imexpharm's Cyclically Adjusted Revenue per Share of ₫11,776.55 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Imexpharm and its competitors. Imexpharm's current Cyclically Adjusted Revenue per Share is ₫11,776.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫52,149.61, compared to a current price of ₫42,950.00 — trading 17.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₫11,776.55. Imexpharm's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Cyclically Adjusted Revenue per Share is ₫11,776.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫42,950.00 is trading 17.6% below its estimated GF Value™ of ₫52,149.61. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Cyclically Adjusted Revenue per Share: ₫11,776.55
  • GF Value™: ₫52,149.61 vs. price of ₫42,950.00 (17.6% below fair value)
  • GF Score™: 97/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
97GF Score

Get the complete analysis for STC:IMP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫42,950.00
Price
₫52,149.61
GF Value